Möchten Sie immer auf dem neuesten Stand bleiben?

AUSTIN, TX, April 22, 2025 (GLOBE NEWSWIRE) -- Telnyx, the full-stack communications platform for AI-powered voice, messaging, and automation, today announced the beta release of its Local Model...

Dublin, April 14, 2025 (GLOBE NEWSWIRE) -- The "Premium Messaging Market Size, Share & Trends Analysis Report By Product (A2P SMS, A2P MMS, P2A SMS, P2A MMS), By Application (BFSI, Retail,...

What you need to know: Verizon Business Assistant is an easy-to-deploy solution that small businesses can start using immediately to free up time and answer customer questions via text...

RESTON, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Carahsoft Technology Corp., The Trusted Government IT Solutions Provider®, today announced Twilio’s customer engagement platform has been added to...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and...

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO Lusvertikimab achieved statistical significance on...

ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn De nouvelles...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on...